CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure ...
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters ...
Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath ® Lung diagnostic test
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...
Company achieves 86% increase in CyPath® Lung testing revenue, strengthens balance sheet
Australian patent strengthens global patent portfolio
Visit the CyPath® Lung team at Booth #2242 October 19-22
U.S. award protects AI-built platform and adds to growing international patent portfolio
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung , the Company’s...